Abstract

The search for effective drugs to treat pre-eclampsia remains ongoing, yet developing new treatments for obstetric conditions poses significant challenges. Drug repurposing emerges as a viable alternative to these challenges. Notably, metformin, a complex I inhibitor, has recently demonstrated potential in addressing pre-eclampsia. Through a comprehensive literature review, pyrvinium was identified as the sole complex I inhibitor deemed safe during pregnancy that has yet to be explored for pre-eclampsia treatment. This paper presents a compelling case for conducting mechanistic and efficacy studies on pyrvinium, leveraging its robust pharmacological attributes and proven safety record.